

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULPHATE ORALLY DISINTEGRATING TABLETS OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that dextromethorphan hydrobromide and quinidine sulphate orally disintegrating tablets (dextromethorphan hydrobromide 20 mg/quinidine sulphate 10 mg) (the “**Product**”), a new Class 2.2 chemical drug developed by the Group, has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trial in China.

The Product is a nervous system drug. The indication for this clinical trial approval is pseudobulbar affect (PBA), also known as pseudobulbar palsy. The Product utilizes self-developed taste-blocking technology, which effectively overcomes the unique bitter and numbing taste of the active pharmaceutical ingredients. In comparison to the conventional capsules dosage form, it has the characteristic of administration without water. It is expected to solve the difficulties in swallowing medications for PBA patients with dysphagia. Currently, there is no orally disintegrating tablets of this drug available in the global market.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 12 December 2023

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.